Gene · 1871
Papers3,808
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,808
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers. | Clin Exp Med | 2024 | 38294554 | PubTator, text mining | PubMed |
| Hsa_circ_0092856 Promoted the Proliferation, Migration, and Invasion of NSCLC Cells by Up-Regulating the Expression of eIF3a. | Biomedicines | 2024 | 38275418 | PubTator, text mining | PubMed |
| Inhibiting the m6A Reader IGF2BP3 Suppresses Ovarian Cancer Cell Growth via Regulating PLAGL2 mRNA Stabilization. | World J Oncol | 2024 | 38274714 | PubTator, text mining | PubMed |
| Serum microRNA Profiles and Pathways in Hepatitis B-Associated Hepatocellular Carcinoma: A South African Study. | Int J Mol Sci | 2024 | 38256049 | PubTator, text mining | PubMed |
| Differential microRNA Expression Analysis in Patients with HPV-Infected Ovarian Neoplasms. | Int J Mol Sci | 2024 | 38255835 | PubTator, text mining | PubMed |
| Y-Box Binding Protein 1: Unraveling the Multifaceted Role in Cancer Development and Therapeutic Potential. | Int J Mol Sci | 2024 | 38255791 | PubTator, text mining | PubMed |
| E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma. | Medicine (Baltimore) | 2024 | 38241554 | PubTator, text mining | PubMed |
| E2F3/5/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer. | Medicine (Baltimore) | 2024 | 38215110 | PubTator, text mining | PubMed |
| Human adenovirus oncolytic properties and the inhibitory role of E4 orf4 and E4 orf6/7 on endogenously activated NF-κB. | Biochem Biophys Rep | 2024 | 38205184 | PubTator, text mining | PubMed |
| Transcription factor E2F3 activates CDC25B to regulate DNA damage and promote mitoxantrone resistance in stomach adenocarcinoma. | Mol Biol Rep | 2024 | 38194158 | PubTator, text mining | PubMed |
| miRNAs as predictive biomarkers of response to treatment in pediatric patients with acute lymphoblastic leukemia. | Oncol Lett | 2024 | 38192661 | PubTator, text mining | PubMed |
| Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor. | Cell Rep Med | 2024 | 38183981 | PubTator, text mining | PubMed |
| The Potential of Aqueous Humor Sampling in Diagnosis, Prognosis, and Treatment of Retinoblastoma. | Invest Ophthalmol Vis Sci | 2024 | 38180770 | PubTator, text mining | PubMed |
| Glutamine addiction in tumor cell: oncogene regulation and clinical treatment. | Cell Commun Signal | 2024 | 38172980 | PubTator, text mining | PubMed |
| Oncogenic lncRNA FAM215A promotes the malignant cell phenotypes of acute myeloid leukemia (AML) cell lines. | J Mol Histol | 2024 | 38165572 | PubTator, text mining | PubMed |
| Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response. | Noncoding RNA Res | 2024 | 38075202 | PubTator, text mining | PubMed |
| Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene. | Breast Cancer Res Treat | 2024 | 38057687 | PubTator, text mining | PubMed |
| Low circulating levels of miR-17 and miR-126-3p are associated with increased mortality risk in geriatric hospitalized patients affected by cardiovascular multimorbidity. | Geroscience | 2024 | 38008859 | PubTator, text mining | PubMed |
| MiR-210-3p enhances intermittent hypoxia-induced tumor progression via inhibition of E2F3. | Sleep Breath | 2024 | 37775619 | PubTator, text mining | PubMed |
| Prognostic and clinical value of circPRKCI expression in diverse human cancers. | Chin Med J (Engl) | 2024 | 37718264 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1871/papers?page=6